【摘要】 目的:探讨卵巢癌c-erbB-2癌基因扩增的临床意义。方法:应用差别PCR技术检测36例原发性卵巢癌c-erbB-2癌基因的扩增情况。结果:(1)卵巢癌组织中c-erbB-2癌基因的扩增率为58.3%(21/36);(2)肿块≥5 cm的卵巢癌组织及中晚期卵巢癌患者c-erbB-2癌基因扩增率分别为67.9%、73.9%,明显高于肿块<5 cm的卵巢癌组织25.0%的扩增率和早期卵巢癌患者30.8%的扩增率,均有显著差异(P<0.05);(3)卵巢癌组织中c-erbB-2癌基因扩增与患者年龄、病理类型、淋巴转移、雌激素受体(ER)及孕激素受体(PR)无相关性。结论:c-erbB-2癌基因扩增与卵巢癌的发生有一定关系,c-erbB-2癌基因扩增对卵巢癌的治疗、预后判断具有重要的临床应用意义。更多还原

【Abstract】 Objective: To explore the clinical significance of c-erbB-2 oncogene amplification in ovarian carcinoma.Methods: c-erbB-2 oncogene amplification was examined by using differential polymerase chain reation in 36 cases of ovarian carcinoma.Results:(1) c-erbB-2 amplification was found in 58.3%(21/36)of ovarian carcinoma.(2) The positive expression rate of c-erbB-2 in patients with ≥5cm tumor size and in the late stage was 67.9%and73.9%,respectively,higher than that in those with〈5cm tumor size(25.0%)and in the early stage(30.8%).(3)c-erbB-2 oncogene amplification was not correlated to the age,pathhological patterns,lymphatic transfer,estrogen receptor(ER) and progestogen receptor(PR).Conclusion: The results suggest that c-erbB-2 amplification plays a role in the process of ovarian carcinoma and may be one of those significant prognostic factors for treating and predicting prognosis of ovarian carcinoma.更多还原